Company Profile
X4 Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- XFOR
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
4.17 USD (+0.48%)
Close
Last updated: August 6, 2026
381M USD
Market cap
Why the stock is moving
The latest monitored company update is “X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update.” The corresponding closing-price reaction is not yet available.
Company overview
Rare Hematology Focus
X4 Pharmaceuticals develops therapies for rare disorders in which dysregulated CXCR4 signaling contributes to abnormal retention of immune cells in bone marrow. Its lead molecule, mavorixafor, is an oral CXCR4 antagonist designed to mobilize neutrophils into circulation.
Chronic Neutropenia Development
Mavorixafor is being evaluated in the global pivotal 4WARD Phase 3 trial for congenital, acquired primary autoimmune and idiopathic chronic neutropenia. The study tests once-daily mavorixafor, with or without G-CSF, in patients who experience recurrent or serious infections.
Approved WHIM Syndrome Product
Mavorixafor is approved as XOLREMDI for WHIM syndrome, including authorization in the European Union. X4 has partnered with Norgine for European commercialization, giving the company a partner-led route to expand access while concentrating internal resources on clinical development.
Future catalysts
Completion of enrollment in the 4WARD Phase 3 chronic neutropenia trial expected by the end of the third quarter of 2026.
Transfer of the European XOLREMDI marketing authorization to Norgine planned later in 2026.
Recent news
- 01
X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Source: X4 Pharmaceuticals
- 02
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Source: X4 Pharmaceuticals
- 03
X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors
Source: X4 Pharmaceuticals
- 04
X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
Source: X4 Pharmaceuticals
- 05
X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
Source: X4 Pharmaceuticals
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of X4 Pharmaceuticals (XFOR)?
X4 Pharmaceuticals (XFOR) most recently closed at 4.17 USD, a +0.48% move versus the previous session.
What is the market cap of X4 Pharmaceuticals (XFOR)?
X4 Pharmaceuticals currently has a market capitalization of 381M USD on BioPharmSignal.
What does X4 Pharmaceuticals do?
Rare Hematology Focus X4 Pharmaceuticals develops therapies for rare disorders in which dysregulated CXCR4 signaling contributes to abnormal retention of immune cells in bone marrow. Its lead molecule, mavorixafor, is an oral CXCR4 antagonist designed to mobilize neutrophils into circulation. Chronic Neutropenia Development Mavorixafor is being evaluated in...
On which exchange is XFOR stock listed?
X4 Pharmaceuticals (XFOR) is associated with NASDAQ, United States, Biopharma.
What is Rare?
Rare Hematology Focus X4 Pharmaceuticals develops therapies for rare disorders in which dysregulated CXCR4 signaling contributes to abnormal retention of immune cells in bone marrow.
Which conditions is X4 Pharmaceuticals targeting with Rare?
X4 Pharmaceuticals is associated with hematology based on its company overview and current catalyst commentary.
How does X4 Pharmaceuticals describe recent progress with Rare?
Completion of enrollment in the 4WARD Phase 3 chronic neutropenia trial expected by the end of the third quarter of 2026. Transfer of the European XOLREMDI marketing authorization to Norgine planned later in 2026.
What is Hematology?
Rare Hematology Focus X4 Pharmaceuticals develops therapies for rare disorders in which dysregulated CXCR4 signaling contributes to abnormal retention of immune cells in bone marrow.